MDT-AP-3073
Med · Medulloblastoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Med
- cancer_type_detailed
- —
- subtype
- Medulloblastoma
- cancer_type
- Med
- subtype
- Medulloblastoma
- age_years
- 31.9
- sex
- M
- new_clusters
- S2
- umap1_2d
- -0.410821498
- umap2_2d
- -10.52911087
- umap1_3d
- -3.584952877
- umap2_3d
- -0.485237764
- umap3_3d
- 5.256605217
- dataset
- Med-Taylor
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.450
- UV_RESPONSE_DN+0.440
- MYC_TARGETS_V1+0.390
- PROTEIN_SECRETION+0.360
- ANDROGEN_RESPONSE+0.330
- ALLOGRAFT_REJECTION+0.310
- E2F_TARGETS+0.260
- INFLAMMATORY_RESPONSE+0.260
- KRAS_SIGNALING_UP+0.250
- G2M_CHECKPOINT+0.230
Top 10 suppressed
- FATTY_ACID_METABOLISM-0.140
- HEME_METABOLISM-0.110
- SPERMATOGENESIS-0.110
- UV_RESPONSE_UP-0.090
- DNA_REPAIR-0.070
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.070
- PEROXISOME-0.050
- TNFA_SIGNALING_VIA_NFKB-0.040
- XENOBIOTIC_METABOLISM-0.040
- APICAL_SURFACE-0.030
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MDT-AP-3095 | Med | Medulloblastoma | 0.851 |
| 2 | MDT-AP-3324 | Med | Medulloblastoma | 0.827 |
| 3 | MDT-AP-2865 | Med | Medulloblastoma | 0.820 |
| 4 | MDT-AP-0006 | Med | Medulloblastoma | 0.820 |
| 5 | C6888F62-AE14-4F73-A1B8-2CB81E2809FD | — | — | 0.818 |
| 6 | MDT-AP-3069 | Med | Medulloblastoma | 0.807 |
| 7 | BS_BVSW4GTG | Med | Medulloblastoma | 0.793 |
| 8 | TCGA-50-6595-01A-12R-1858-07 | — | cohortA1 | 0.790 |
| 9 | MDT-AP-3263 | Med | Medulloblastoma | 0.786 |
| 10 | MDT-AP-3337 | Med | Medulloblastoma | 0.781 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 37 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.450 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.440 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.390 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.360 | Remibrutinib | — uncovered |
| ANDROGEN_RESPONSE | 0.330 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.310 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.260 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.260 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.250 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.230 | Inavolisib | — uncovered |
| COMPLEMENT | 0.220 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.220 | Cobimetinib | — uncovered |
| MITOTIC_SPINDLE | 0.210 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.190 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.180 | Remibrutinib | — uncovered |
| HEDGEHOG_SIGNALING | 0.180 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.180 | Idelalisib | — uncovered |
| COAGULATION | 0.170 | Binimetinib | — uncovered |
| APOPTOSIS | 0.160 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.150 | Inavolisib | — uncovered |